Health and effects
Cannabinoids and REM sleep
What studies can tell us about cannabinoids and REM sleep, including human research, early evidence, and important limits.
The short answer
What does the research say about REM sleep?
Researchers have studied cannabinoids in connection with REM sleep. The current literature covers CBD, THC, CBN, and Oleamide. This page brings together 5 human-study sources, 1 research review, and 1 lab, animal, or mechanism source. It includes 9 specific study findings from 5 sources. The source set includes human research as well as earlier-stage studies. There is no single answer that applies to every cannabinoid, dose, product, or person. 1
Key takeaways
What to know first
- 1
Research on REM sleep covers CBD, THC, and CBN; those areas should not be combined into one claim. 1
- 2
The source set includes human research as well as earlier-stage studies. 2
- 3
Dose, formulation, route, study population, and outcome can change how closely a study applies to a real-world question. 3
Research areas
What researchers studied about REM sleep
These are the main questions represented in the current literature. Each link opens a source used to build the overview.
Human research included
CBD
Researchers have studied CBD in connection with REM sleep. The exact compound, dose, formulation, sleep or health measure, and study design determine what the source can show. 3
Human research included
THC
Researchers have studied THC in connection with REM sleep. The exact compound, dose, formulation, sleep or health measure, and study design determine what the source can show. 2
Mostly preclinical
CBN
Researchers have studied CBN in connection with REM sleep. The exact compound, dose, formulation, sleep or health measure, and study design determine what the source can show. 5
Too limited for a firm answer
Oleamide
Researchers have studied Oleamide in connection with REM sleep. The exact compound, dose, formulation, sleep or health measure, and study design determine what the source can show. 6
Results extracted so far
What did the studies report?
These summaries appear only when the recorded study outcome is specific enough to reproduce from the linked source. If a source has no result summary here, the result has not been extracted yet; that does not mean the study found no effect.
-
In a single case report involving one patient with treatment-refractory isolated REM sleep behavior disorder, researchers reported a decrease in dream-enactment behavior in a treatment-refractory RBD case following not stated in the PubMed abstract by the oral tincture route over 5 years of follow-up. The recorded comparator was none. 1
Recorded result: The case was described as having dramatic and sustained improvement without adverse events.
-
In a randomized placebo-controlled crossover pilot trial involving 20 adults with DSM-5 insomnia disorder, researchers reported a decrease in total sleep time after an acute THC-CBD dose following 10 mg THC and 200 mg CBD once by the oral route over single study night. The recorded comparator was placebo. 2
Recorded result: Total sleep time decreased by 24.5 minutes (P=.05; d=-.5).
-
In a randomized placebo-controlled crossover pilot trial involving 20 adults with DSM-5 insomnia disorder, researchers did not detect a difference in subjective sleep quality after an acute thc-cbd dose following 10 mg THC and 200 mg CBD once by the oral route over single study night. The recorded comparator was placebo. 2
Recorded result: No change in subjective sleep quality was detected.
-
In a randomized double-blind placebo-controlled crossover clinical trial involving 125 people with insomnia, researchers reported an increase in combined slow-wave and REM sleep percentage following 300 mg CBD plus 1 mg each of eight terpenes per administration by the oral route over 4 weeks. The recorded comparator was placebo. 3
Recorded result: Mean difference 1.3 percentage points (SE 0.60; 95% CI 0.1 to 2.5; P=0.03).
-
In a randomized double-blind placebo-controlled crossover clinical trial involving 125 people with insomnia, researchers did not detect a difference in total sleep time following 300 mg CBD plus 1 mg each of eight terpenes per administration by the oral route over 4 weeks. The recorded comparator was placebo. 3
Recorded result: The abstract reports no detected effect on total sleep time.
-
In a case series involving 4 patients with Parkinson disease and REM sleep behavior disorder, researchers reported a decrease in REM sleep behavior disorder event frequency in Parkinson disease following not stated in the PubMed abstract over not stated in the PubMed abstract. The recorded comparator was none. 4
Recorded result: All four cases were described as having prompt and substantial reductions; no numerical estimate was reported.
-
In a rat polysomnography study, researchers reported more total sleep time. This does not establish the same result in people. 5
-
In a rat polysomnography study, researchers reported more NREM sleep. This does not establish the same result in people. 5
-
In a rat polysomnography study, researchers reported more REM sleep. This does not establish the same result in people. 5
How strong is the research?
Not every study answers the same question
This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.
Human studies
Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.
Reviews and evidence summaries
Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.
Lab, animal, and mechanism research
Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.
Another 1 of 8 research source could not be placed cleanly into those three groups from the recorded study details.
What these studies actually looked at
The research on REM sleep is not one kind of study. This source set includes 3 clinical studies in people, 1 case series, 1 mechanism-focused study, and 1 narrative or expert review. 3
The recorded populations or models include people or patients (4 sources), 125 people with insomnia (1 source), and 20 adults with DSM-5 insomnia disorder (1 source). A result from one group or model should not be assumed to apply to another. 4
The most common recorded outcome focus is sleep-related outcomes (3 sources), oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms (2 sources), and total sleep time (2 sources). Closely related outcome names can still describe different measurements. 5
Some source records specify doses including not stated in the PubMed abstract (2 sources), 10 mg THC and 200 mg CBD once (1 source), and 300 mg CBD plus 1 mg each of eight terpenes per administration (1 source). These are descriptions of what researchers tested, not personal dosing instructions. 6
The REM sleep source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 7
Examples from the literature
What did the studies actually look at?
Each example names the research question and the study details recorded for that source.
single case report
The use of cannabinoid therapy in treatment-refractory isolated REM sleep behavior disorder: a case report.
On this page, this source examines CBD and dream-enactment behavior in a treatment-refractory RBD case. 1
- Study type
- single case report
- Population or model
- people or patients
- Outcome focus
- dream-enactment behaviors
- Dose recorded
- not stated in the PubMed abstract
- Evidence stage
- human research
clinical study in people
Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.
On this page, this source examines CBD and sleep, THC and sleep, and CBD and total sleep time after an acute THC-CBD dose and other related questions. 2
- Study type
- clinical study in people
- Population or model
- people or patients and 20 adults with DSM-5 insomnia disorder
- Outcome focus
- sleep-related outcomes and high-density EEG total sleep time and other recorded details
- Dose recorded
- 10 mg THC and 200 mg CBD once
- Evidence stage
- human research
clinical study in people
Effects of a cannabidiol/terpene formulation on sleep in individuals with insomnia: a double-blind, placebo-controlled, randomized, crossover study.
On this page, this source examines CBD and sleep, CBD and combined slow-wave and REM sleep percentage, and CBD and total sleep time. 3
- Study type
- clinical study in people
- Population or model
- 125 people with insomnia
- Outcome focus
- sleep-related outcomes and wrist-tracker percentage of time in combined slow-wave and REM sleep and other recorded details
- Dose recorded
- 300 mg CBD plus 1 mg each of eight terpenes per administration
- Evidence stage
- human research
case series
Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series.
On this page, this source examines CBD and rEM sleep behavior disorder event frequency in Parkinson disease. 4
- Study type
- case series
- Population or model
- people or patients
- Outcome focus
- frequency of RBD-related events
- Dose recorded
- not stated in the PubMed abstract
- Evidence stage
- human research
rat polysomnography study
A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats
On this page, this source examines CBN and total sleep time, CBN and nREM sleep, and CBN and rEM sleep and other related questions. 5
- Study type
- rat polysomnography study and mechanism-focused study
- Population or model
- rats
- Outcome focus
- total sleep time and nREM sleep and other recorded details
- Evidence stage
- preclinical research and mechanism-focused research
Safety and limits
What should readers keep in mind?
Research on REM sleep should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 6
Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.
Common questions
Questions people ask
Can cannabinoids help with REM sleep?
Research exists, but there is not one answer for every cannabinoid or product. The source set includes human research as well as earlier-stage studies. 7
Why can studies reach different answers?
Studies may test different cannabinoids, doses, formulations, routes, people, and outcomes. Those differences can change the result. 8
What should I check in a study?
Check whether it studied people, what product and dose it used, what it measured, how long it lasted, and whether safety was reported. 1
Sources
Read the research
The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.
-
1
The use of cannabinoid therapy in treatment-refractory isolated REM sleep behavior disorder: a case report. single case report; human research PubMed 40130438 DOI 10.5664/jcsm.11704
-
2
Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial. clinical study in people; human research PubMed 40631525 DOI 10.1111/jsr.70124
-
3
Effects of a cannabidiol/terpene formulation on sleep in individuals with insomnia: a double-blind, placebo-controlled, randomized, crossover study. clinical study in people; human research PubMed 39167421 DOI 10.5664/jcsm.11324
-
4
Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series. case series; human research PubMed 24845114 DOI 10.1111/jcpt.12179
-
5
A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats rat polysomnography study; mechanism-focused study; preclinical research; mechanism-focused research PubMed 39528623 DOI 10.1038/s41386-024-02018-7
-
6
Oleamide: an endogenous sleep-inducing lipid and prototypical member of a new class of biological signaling molecules. narrative or expert review; evidence still limited PubMed 10197045
-
7
Cannabinol (CBN; 30 and 300 mg) effects on sleep and next-day function in insomnia disorder ('CUPID' study): protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trial. clinical study in people; evidence still limited PubMed 37612115 DOI 10.1136/bmjopen-2022-071148
-
8
Cannabinoids and Sleep/Wake Control. evidence still limited PubMed 33537938 DOI 10.1007/978-3-030-61663-2_6
See all 8 research sources
This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.
- A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats rat polysomnography study; mechanism-focused study; preclinical research; mechanism-focused research / 4 linked research notes PubMed 39528623
- Cannabinol (CBN; 30 and 300 mg) effects on sleep and next-day function in insomnia disorder ('CUPID' study): protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trial. clinical study in people; evidence still limited / 1 linked research note PubMed 37612115
- Effects of a cannabidiol/terpene formulation on sleep in individuals with insomnia: a double-blind, placebo-controlled, randomized, crossover study. clinical study in people; human research / 3 linked research notes PubMed 39167421
- Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial. clinical study in people; human research / 4 linked research notes PubMed 40631525
- Oleamide: an endogenous sleep-inducing lipid and prototypical member of a new class of biological signaling molecules. narrative or expert review; evidence still limited / 1 linked research note PubMed 10197045
- Cannabinoids and Sleep/Wake Control. evidence still limited / 1 linked research note PubMed 33537938
- Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series. case series; human research / 1 linked research note PubMed 24845114
- The use of cannabinoid therapy in treatment-refractory isolated REM sleep behavior disorder: a case report. single case report; human research / 1 linked research note PubMed 40130438